ADMA BiologicsADMA
About: ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.
Employees: 685
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
312% more call options, than puts
Call options by funds: $67.2M | Put options by funds: $16.3M
89% more first-time investments, than exits
New positions opened: 68 | Existing positions closed: 36
20% more funds holding in top 10
Funds holding in top 10: 5 [Q4 2024] → 6 (+1) [Q1 2025]
15% more capital invested
Capital invested by funds: $3.5B [Q4 2024] → $4.04B (+$539M) [Q1 2025]
13% more repeat investments, than reductions
Existing positions increased: 126 | Existing positions reduced: 112
8% more funds holding
Funds holding: 319 [Q4 2024] → 345 (+26) [Q1 2025]
0.25% less ownership
Funds ownership: 86.29% [Q4 2024] → 86.04% (-0.25%) [Q1 2025]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Raymond James Elliot Wilbur | 72%upside $32 | Strong Buy Maintained | 8 May 2025 |
Financial journalist opinion
Based on 7 articles about ADMA published over the past 30 days
